Global Health
Innovative Matrix Framework Assesses Risk for Substandard Antibiotics...
Substandard medicines are a huge public health threat. Proactively evaluating drug products using a relative risk assessment is important to reduce the prevalence of substandard antibiotics.
Tackling medicine supply shortages starting with their ingredients ...
How to secure upstream pharmaceutical supply chain risks with data and advanced technologies to increase access to quality medical products for patients
Four global health resolutions for 2022
We have an incredible opportunity to leverage the lessons of the last year to make an even greater impact in 2022. At USP, we are resolving to accelerate our global health efforts in four central areas.
Manufacturing COVID-19 vaccines in Africa
While the global vaccination effort to curb the spread of COVID-19 continues to ramp up worldwide, access to COVID-19 vaccines, particularly in low- and middle-income countries, remains staggeringly low. In fact, low- and middle-income countries received less than one percent of available doses.
Q&A: Impact of Quality Medicines on AMR
Q&A with Georgetown University researchers Matthew Hassett, Ph.D. and Professor Paul Roepe, Ph.D.
Assuring Medicines Quality in Medicines Procurement Report...
Universal health coverage requires access to quality-assured medicines. Unfortunately, substandard and falsified medicines are highly preval
Medicine Quality Must Be Assured, Not Assumed
When a problem puts millions of lives at risk, costs economies billions of dollars and undermines decades of hard-earned health progress, it deserves prompt and strategic attention. I’m describing the consequences of poor-quality medicines – a worldwide problem that deserves worldwide attention.
Opioid Crisis: USP’s Comments to the FDA
As government agencies consider solutions to the growing opioid crisis, the Food and Drug Administration (FDA) recently sought public comment about ways to best address this national emergency.